Want to see GB:KMK full AI Analyst Report?
KMK Stock Chart & Stats
8.00 p
-0.10 p(-1.25%)
At close: 4:00 PM EDT
8.00 p
-0.10 p(-1.25%)
Day’s Range― - ―
52-Week Range5.40 p - 13.00 p
Previous CloseN/A
Volume483.86K
Average Volume (3M)1.99M
Market Cap
£36.70M
Enterprise Value47.71M
Total Cash (Recent Filing)£4.16M
Total Debt (Recent Filing)£9.36M
Price to Earnings (P/E)49.1
Beta1.06
Next Earnings
Feb 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding655,299,900
10 Day Avg. Volume1,841,606
30 Day Avg. Volume1,987,786
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.26
Price to Sales (P/S)2.53
P/FCF Ratio25.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£30.30M
Bulls Say, Bears Say
Bulls Say
Return To ProfitabilityThe return to positive net income after heavy losses in 2021–2024 demonstrates meaningful operational progress. Although recent profitability is thin, the turnaround provides a stronger base for funding development, serving customers, and rebuilding earnings power over the next several quarters.
Conservative Balance SheetModest leverage and a sizeable equity base give Kromek financial flexibility as it develops and sells specialised radiation detection technology. Lower debt exposure can reduce solvency pressure, preserve borrowing capacity, and help the company withstand uneven operating performance.
Positive Cash GenerationDespite a substantial year-on-year decline, positive free cash flow means the business continued to convert its operations into cash during 2026. That supports ongoing investment and customer delivery without relying entirely on external funding, provided cash conversion stabilises.
Bears Say
Revenue ContractionA 28.3% revenue decline indicates that demand, customer timing, or contract delivery was materially weaker in the latest year. Sustained contraction would reduce operating leverage, constrain investment in detector technology, and make a durable earnings recovery harder to achieve.
Margin CompressionThe sharp reduction in gross and net margins shows that recent profitability is not yet firmly established. Lower margins leave less protection against revenue volatility, reduce funds available for research and development, and increase the sensitivity of earnings to product mix and execution.
Unreliable Cash ConversionThe collapse in cash generation from 2025 to 2026 highlights considerable volatility in cash conversion. Even though free cash flow stayed positive, weaker internally generated funds could limit investment capacity and make future growth more dependent on improved trading or external financing.
Kromek Group plc News
KMK FAQ
What was Kromek Group PLC’s price range in the past 12 months?
Kromek Group PLC lowest share price was 5.40 p and its highest was 13.00 p in the past 12 months.
What is Kromek Group PLC’s market cap?
Kromek Group PLC’s market cap is £36.70M.
When is Kromek Group PLC’s upcoming earnings report date?
Kromek Group PLC’s upcoming earnings report date is Feb 02, 2027 which is in 102 days.
How were Kromek Group PLC’s earnings last quarter?
Kromek Group PLC released its earnings results on Sep 14, 2026. The company reported -0.004 p earnings per share for the quarter.
Is Kromek Group PLC overvalued?
According to Wall Street analysts Kromek Group PLC’s price is currently Overvalued.
Does Kromek Group PLC pay dividends?
Kromek Group PLC does not currently pay dividends.
What is Kromek Group PLC’s EPS estimate?
Kromek Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kromek Group PLC have?
Kromek Group PLC has 655,299,900 shares outstanding.
What happened to Kromek Group PLC’s price movement after its last earnings report?
Kromek Group PLC reported an EPS of -0.004 p in its last earnings report. Following the earnings report the stock price went down -3.776%.
Which hedge fund is a major shareholder of Kromek Group PLC?
Currently, no hedge funds are holding shares in GB:KMK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kromek Group plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.12%
12-Months-Change
Fundamentals
Return on Equity
1.32%
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kromek Group PLC
Kromek Group plc, a UK-based entity established in 2013 with headquarters in Sedgefield, specializes in the design, production, and global distribution of advanced radiation detection components and devices. These technologies provide high-resolution data on material composition and structure, serving critical applications across diverse markets such as medical imaging, the civil nuclear sector, CBRNe security, and safety screening. Its reach extends across the United Kingdom, North America, Asia, Europe, Australasia, and Africa. The company's innovative solutions are employed for various purposes, from identifying cancerous tissues and hazardous substances like explosives, to analyzing radioactive materials. Within the civil nuclear industry, Kromek offers sophisticated gamma and neutron detectors, high-specification, high-resolution devices, essential components, and specialized software designed to address complex nuclear detection challenges. These often utilize cadmium zinc telluride (CZT) or scintillator technologies for the detection of gamma rays, x-rays, and neutrons. For medical imaging, their portfolio includes CZT gamma detectors for SPECT, CZT bone mineral densitometry detectors, and cutting-edge photon-counting spectral CT systems. Kromek also provides CBRNE homeland security products and comprehensive solutions for a wide range of clients, including government agencies, border control, airports, seaports, HazMat teams, ambulance crews, police, and armed forces. This offering features specialized gamma spectroscopy software for in-depth sample analysis. Furthermore, the company supports scientific research and development through its CZT imaging development platforms, such as the DMatrix and the EV3500 scalable x-ray CZT linear array, designed for laboratory and research applications. Kromek distributes its products through a combination of distributors, original equipment manufacturers (OEMs), and direct sales channels.
Technical Analysis
Gooch & Housego
―
Judges Scientific
―
TT Electronics
―
Windar Photonics
―
discoverIE Group plc
―






